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Frequent reduction or loss of DCC gene expression in
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Summary The 'deleted in colon carcinoma' (DCC) gene has been considered a candidate tumour-suppressor gene that encodes for a
transmembrane protein with strong structural similarity to members of the superfamily of neural cell adhesion molecules. It has been mapped
to the chromosomal region 18q21 .1 and it is implicated in cellular differentiation and developmental processes. In human osteosarcoma allelic
loss frequently occurs on the long arm of chromosome 18, suggesting a possible involvement of the DCC gene in the pathogenesis of this
tumour entity. In the present study the mRNA and protein expression and rearrangements at the DNA level of the DCCgene were addressed
in 25 osteosarcomas and several tumour cell lines, including osteosarcoma- and colon carcinoma-derived cell lines. Using an reverse
transcriphase polymerase chain reach in (RT-PCR)-based approach DCCexpression was found to be lost or substantially reduced in 14 of 19
high-grade osteosarcomas, in three of six lower grade osteosarcomas and most of the tumour cell lines, in contrast to normally differentiated
osteoblasts. Immunohistochemical studies on DCC protein expression of 14 selected tumours correlated well with the RT-PCR-based results.
In view of the putative tumour-suppressor characteristics of the DCCgene its loss or reduction of expression could be a specific event in the
development or progression of many high-grade osteosarcomas.
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Consistent chromosomal losses in human malignancies often
imply that the affected region may contain a tumour-suppressor
gene. In osteosarcomas frequent allelic deletions have been
detected at chromosome arms 3q, 13q, 17p and 18q, the latter of
which has been found to be affected in 7 of 11 investigated
tumours (Yamaguchi et al, 1992). In 1990, a putative tumour-
suppressor gene was identified and has been mapped to the chro-
mosomal region 18q21.1. Based on studies on allelic delections in
colorectal cancer it has been termed 'deleted in colon carcinoma
(DCC) gene' (Fearon et al, 1990).
Its open reading frame comprises 29 exons that encode for a
transmembrane neural cell adhesion molecule consisting of four
immunoglobulin-like and six fibronectin type III-like extracellular
domains and a still poorly characterized intracytoplasmic domain
(Cho et al, 1994). In colorectal cancer a homozygous deletion,
point mutations and DNA insertions have been observed within
the DCCgene. Moreover, loss ofheterozygosity (LOH) and reduc-
tion or loss of expression of the DCC transcript are common in
prostate, breast, oesophageal, endometrial, glial and germ-cell
cancer, as well as some haematological malignancies (Cropp
et al, 1990; Hohne et al, 1992; Uchino et al, 1992; Gao et al, 1993;
Miyake et al, 1993; Porfiri et al, 1993; Scheckr Coons, 1993;
Thompson et al, 1993).
Results of functional in vitro studies such as cytomegalovirus
expression vector-mediated DCC cDNA transfection experiments or
antisense RNA strategies to DCC endorse its role as a tumour-
suppressor gene (Narayanan etal, 1992; Klingelhutz etal, 1995). The
DCC gene has been implicated in terminal cellular differentiation
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and developmental processes, perhaps through control ofcell-cell or
cell-extracellular matrix interactions. Like other cell adhesion mole-
culesDCCis expressed atthe cell surface but atrelatively low levels,
thus suggesting thatits role may ratherbethatofasignal-transducing
receptor than an anchorage protein mechanically preserving cellular
texture (Hedrick et al, 1994). Its loss may confer a growth advantage
on evolving cells.
In human osteosarcoma the frequently observed loss of heter-
ozygosity at chromosome arms 13q and 17p may involve the
retinoblastoma and p53 tumour-suppressor genes (Friend et al,
1986; Toguchida et al, 1989; Miller et al, 1990; Mulligan et al,
1990) whereas the candidate genes within the LOH loci at chro-
mosome arms 3q and 18q are still undefined. The localization of
the DCC gene at the chromosomal region 18q21.1 may suggest its
involvement in the pathogenesis of this tumour entity. To prove
this hypothesis we assessed 25 specimens ofhuman osteosarcoma
from 22 patients and various osteosarcoma- and other childhood
sarcoma-derived cell lines with regard to mRNA and protein
expression and DNA rearrangement of the DCC gene. Various
normally differentiated mesenchymal tissues, including osseous
specimens and several colon carcinoma cell lines with known
expression pattems of the DCC gene (Fearon et al, 1990) were
included in the study.
MATERIALS AND METHODS
Tissue specimens
Twenty-five human osteosarcomas were obtained from 22 patients
who underwent surgery at the University Clinic Hamburg-
Eppendorf or associated treatment centres of the Cooperative
Osteosarcoma Study Group (Winkler et al, 1988). The selection of
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Table 1 Clinicopathological data
OS Patient No. Age at Primary Specimen Histological subtype Chemotherapya Admixture of
no. diagnosis tumour (grading) before sampling non-malignant
(years) cells
1 1 22 Femur p High-grade chondroblastic + (-)
2 2 14 Femur p High-grade osteoblastic + (-) pb
3 3 17 Femur m (lung) High-grade chondroblastic - (-)
4 4 52 Femur p High-grade osteoblastic - (-)
5c 5 15 Femur m (lung) High-grade osteoblastic - (-)
6 6 33 NE m (spine) High-grade osteoblastic + (-)
7 7 16 Tibia p High-grade osteoblastic + (-)
8 8 18 Femur m (lung) High-grade osteoblastic - (-)
9 9 14 Humerus p High-grade osteoblastic + (-)
10 10 8 Humerus p High-grade osteoblastic + 10-15%
11 11 9 Secondary OS after RB p High-grade osteoblastic + (-)
12 12 NE Femur m (lung) High-grade osteoblastic - (-)
13 13 20 Femur p High-grade chondroblastic + (_)b
14 14 15 Femur p High-grade chondroblastic + <10%
15 15 85 NE p High-grade osteoblastic - (-)
16 16 12 Fibula p High-grade osteoblastic + (-)
17 17 13 Tibia p High-grade osteoblastic + (-)
18 18 13 Fibula p High-grade chondroblastic + (-)
19c 5 15 Femur m (lung) High-grade osteoblastic - (-)
20 19 11 Tibia p Intermediate periosteal - (-)
21 19 11 Tibia r Intermediate periosteal - (-)
22 20 7 Femur, secondary OS after RMS p Intermediate periosteal - (-)
23 21 16 Os ileum p Low-grade - (-)
24 22 17 Humerus r Low-grade - (-)
25 22 17 Humerus m (lung) Low-grade - (-)
aAccording to the guidelines of the Cooperative Osteosarcoma Study (COSS 86) (Winkler et al, 1988). p, primary tumour m, metastasis; r, relapse; RB,
retinoblastoma; RMS, rhabdomyosarcoma; NE, not evaluable; (-) absence of significant amounts of non-malignant cells except for stroma cells. bApproximately
20% vital tumour cells and 80% necrosis. cMetachronous lung metastases occurring 7 and 8 years after primary disease respectively.
Table 2 Cell lines
Osteogenic sarcoma TE85, Saos-2, U-2 OS, KHOS-240S,
Wo-OS
Colorectal adenocarcinoma SW48, SW403, SW948, SW1116,
SW1463,
HCT116
Rhabdomyosarcoma A-204
Ewing's sarcoma RD-ES
Acute T-lymphoblastic leukaemia CCRF-CEM
cases was based on the availability offrozen tissue material, which
was stored at -80°C, as well as paraffin-embedded tissue speci-
mens. Each tumour specimen was thoroughly evaluated by micro-
scopic examination, particularly with regard to vitality of tumour
cells and contamination with non-malignant cells. Twenty-one out
of 25 tumours consisted almost exclusively of vital tumour cells
except for an insignificant admixture of stroma cells. As shown in
Table 1 12 tumours were obtained after preoperative chemo-
therapy. Nine of these were non-responsive and contained no
significant normal cell populations. Two tumours (OS10, 14)
contained minor amounts of granulation tissue, whereas two
others (OS 2,13) revealed considerable necrosis. Tumours
revealing more than 90% chemotherapy-induced necrosis or more
than 20% non-malignant vital tissue were excluded from the study.
Clinical and pathological data are summarized in Table 1. In cases
OS II and OS22, a retinoblastoma and a rhabdomyosarcoma
respectively had preceded the development of osteosarcoma. In
three cases two different tumour specimens were collected from
one patient each as indicated by patient numbers in Table 1.
Specimens OS5 and OS19 (patient no.5) were metachronous lung
metastases of a high-grade osteosarcoma that occurred 7 and 8
years after primary disease respectively. Patient no. 19 initially
presented with an intermediate-grade periosteal osteosarcoma
(OS20), which relapsed 4 months after limb-salvaging surgery
(OS21). OS24 and OS25 represent a second local relapse of a low-
grade osteosarcoma and a concomitant lung metastasis, both of
which occurred nearly 2 years after the initial diagnosis.
As a control normal bone tissue devoid of adherent bone
marrow cells was obtained from 11 patients undergoing joint
replacement procedures because of non-inflammatory and non-
malignant joint disease. One case of myositis ossificans was
included to demonstrate differential DCC expression in undiffer-
entiated mesenchymal cells and mature osteoblasts/ osteocytes.
Additionally, paraffin-embedded specimens of granulation tissue
from chemotherapy-responsive osteosarcomas were included as
controls. For RNA studies matching of osteosarcoma and normal
bone tissue in each patient was not feasible because normal bone
tissue was not collected prospectively.
Cell lines
Table 2gives an overview oftheoriginofcell lines usedin this study.
All cell lines were of human origin and were purchased from the
American Type Culture Collection (Rockville, MD, USA) exceptfor
one osteogenic sarcoma derived-cell line referred to as Wo-OS,
which was established in our institution. Osteosarcoma cell lines
Saos-2, U2-OS, Wo-Os, KHOS-240S and the rhabdomyosarcoma
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cell line A-204 were grown in McCoy's 5a medium supplemented
with 10% fetal calf serum (FCS). The osteosarcoma cell line TE85
and the Ewing's sarcoma cell line RD-ES, as well as the T-ALL cell
line CCRF-CEM, were grown in RPMI-1640 with 10-15% FCS.
Colon carcinoma cell lines HCT 116, SW 1463, SW 403, SW 948,
SW 48 and SW 1116 were cultured in MEMIRPMI-1640 (ratio 3:1)
supplemented with 10% FCS.
Total RNA isolation and DNA extraction
Osteosarcoma tissue was submerged in liquid nitrogen and subse-
quently ground to powder by a microdismembrator (Braun Biotech
Int.). Normal cortical bone specimens were smashed to small frag-
ments and subsequently washed twice in Hanks' solution for 30 s
to remove adherent non-osseous cells. Cells were lysed in guani-
dine-thiocyanate buffer. DNA and total RNA were isolated after
ultracentrifugation on a caesium chloride cushion (Chirgwin et al,
1979). In cases of insufficient yield of total RNA we used a
monophasic solution of phenol and guanidine-thiocyanate
(Chomczynski and Sacchi, 1987).
DNA blot analysis
An aliquot of 10 Htg of EcoRI-digested genomic DNA was elec-
trophoresed on a 0.8% agarose gel and transferred to a Gene
Screen Plus nylon membrane (DuPont). Nylon filters were
hybridized with a [32P]-CTP-labelled DCC 1.65kb cDNA probe
comprising nucleotides 591-2250 (exons 3-15) ofthe DCC cDNA
sequence for 18 h at 65°C. Washes and autoradiography were
performed as described previously (Maniatis et al, 1989).
Reverse transcriptase- polymerase chain reaction
(RT-PCR)
An aliquot of 1 gg of total RNA was reverse transcribed. The
synthesis of the first strand cDNA was primed with random hexa-
mers performed at 42°C for 1 h using 200 units M-MLV reverse
transcriptase (Promega, Madison, WI, USA). After RNAase H
treatment of the RNA/DNA hybrid, one half of the cDNA was
used for PCR amplification in a 100-,tl reaction mix containing 50
pmol of each primer, 2.5 U of Taq polymerase (Boehringer,
Mannheim), 200 ,tmol 1-' dNTPs, 10 mmol 1-1 Tris-HCL pH 8.0,
50 mmol 1-1 potassium chloride, 1.5 mmol 1-' Magnesium chloride.
DCC complementary DNA was amplified under the following
conditions: 94°C for 30 s; 58°C for 75 s; 72°C for 30 s for 35
cycles. The initial denaturation was performed at 95°C for 1 min.
For the final extension, temperature was held at 72°C for 5 min.
DCC-specific primers were designed that span exons 5-6 of the
DCC cDNA sequence (nt 986-1218) coding for the extracellular
immunoglobulin-like domains no. 3 and 4 of the DCC protein.
Owing to this exon connection strategy, DNAase I treatment ofthe
initial template had no effect on the resulting PCR products. To
confirm the integrity of the RNA used to generate the cDNAs and
to check for equivalent efficiency of amplification all RT-PCR
experiments were performed using sets ofprimers specific for the
f-actin as well as the glucose 6-phosphate dehydrogenase (G6PD)
housekeeping genes (Persico et al, 1981; Nakajima-lijima et al,
1985; Adams et al, 1992), which are located on chromosomes X
and 7 respectively. Both genes code for highly conserved proteins.
P-Actin is found in abundance in eukaryotic cells, whereas G6PD
is normally expressed at a very low level accounting for less than
0.1I% of total RNA. RT-PCR experiments were done as a biplex
PCR, i.e. PCR reactions were run containing the DCC-specific
primers combined with /B-actin or G6PD specific sets of primers.
To exclude an interference of target and control primers resulting
in a reduced rate of amplification of either gene product the
volume of the RT reaction was split and the cDNAs were ampli-
fied separately with the DCC and control primers respectively.
PCR products were sampled during the exponential phase of
amplification, as could be demonstrated for DCC-specific primers
as well as controls (data not shown). The RT-PCR experiments
were finally carried out twice as a biplex PCR for each sample to
check for reproducible results. Concentrations of control primers
were 25 pmol l-1 each; experiments were performed under the
above-mentioned conditions. Primers used were
5'-TTCCGCCATGGTTTTTAAATCA-3' (DCC sense),
5'-AGCCTCATTTTCAGCCACACA-3' (DCC antisense)
(Fearon et al, 1990),
5'-ATTCATCATCATGGGTGCATCG-3' (G6PD sense),
5'-TGTTTGCGGATGTCAGCCACTGT-3' (G6PD antisense),
5'-TGCTATCCAGGCTGTGCTAT-3' (actin sense),
5'-GATGGAGTTGAAGGTAGTTT-3' (actin antisense).
In order to examine the specificity and the relative amount of
the generated PCR product one-fifth (20 ptl) of each PCR reaction
was electrophoresed and blotted onto a nylon membrane by capil-
lary salt transfer using a lOxSSC solution (lxSSC=0.15 M sodium
chloride/0.015 sodium citrate). Blots were hybridized with Ix106
c.p.m. of the [32P]CTP-labelled 1.65 DCC cDNA probe per ml at
65°C for 16 h. After hybridization blots were washed twice with
0.1xSSC/0.1% sodium dodecyl sulphate (SDS) at 60°C for 30 min
and autoradiographed at 4°C for 12 h. DCC RT-PCR products
from normal bone tissue were included in each set of probes as
a positive control. Furthermore, after stripping off the DCC
cDNA probe the co-amplified f-actin-specific PCR products
were hybridized with 0.5 x 106 c.p.m. per ml of a 31P-labelled
actin probe.
An aliquot of tg oftotal RNA from each normal bone specimen
was reverse transcribed and the prepared cDNAs were serially
diluted from 1:1 to 1:1000, and subsequently amplified under
conditions identical to those described above.
RT-PCR data analysis
The intensity of individual autoradiographic signals of blotted
PCR products was measured by densitometry scanning using a
Shimadzu densitometer. The area under the curve of absorption
(AUC of A) was calculated with computer assistance. In order to
estimate the relative abundance of DCC transcripts, values were
compared with the mean AUCs resulting from the serially diluted
cDNAs from normal bone specimens (Figure 1).
Preparation of cell line and tissue protein lysates
Cell homogenates were solubilized in Tris-buffered saline [25 mm
Tris (hydroxyureaethylaminomethane), pH 8] with detergents (1%
deoxycholate, 1% Nonidet p-40, and 0.1% SDS) and protease
inhibitors (50 ,ug ml-' antipain, 5 Htg ml-' leupeptin, 100 ,ug ml-'
phenylmethylsulfonyl fluoride, and 1 mm EDTA). Protein concen-
trations were determined photometrically after adjustment with
known albumin concentrations.
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Figure 1 PCR amplification yields of serially diluted cDNAs from normal
bone tissue. An aliquot of 1 9g of RNA from 11 normal osseous tissue
specimens was reverse transcribed. Each cDNA was diluted from 1:1 to
1:1000 and thereafter amplified under identical conditions. The graph
illustrates the relationship between the mean absorption of autoradiographic
signals (including standard deviation) and the magnitude of cDNA dilution
shown as its logarithm. Note the maximum of amplification at a DCCcDNA
dilution of about 1:2
Immunoprecipitation and immunoblot analysis of DCC
expression
Unprocessed cell line and tissue lysates were precleared by
incubation with purified mouse immunoglobulin and protein
G/Sepharose (Pharmacia, Germany). The supematant was incu-
bated with protein G/Sepharose and DCC-specific monoclonal
antibodies (15 gg ml', mouse, PharMingen, Hamburg) directed
against extra- and intracytoplasmic domains (DCC antibodies and
protein G/Sepharose were incubated for 4-6 h before). DCC-
specific immunoprecipitates were recovered, washed, resuspended
in Laemmli's sample buffer, and then subjected to SDS polyacry-
lamide gel electrophoresis (PAGE). The protein was transferred to
a nitrocellulose membrane (Schleicher & Schuell, Dassel) by a
semidry transblot system (Biometra, Gottingen). The DCC protein
in the immunoprecipitates was detected by the ECL immunoblot
assay (Amersham, Braunschweig) and subsequent exposure to
Hyperfilm-JMax (Amersham).
Immunohistochemical analysis of DCCexpression
For immunohistochemistry, paraffin-embedded specimens of
osteosarcoma were available from 13 patients. Immuno-
histochemistry (IHC) was performed using the alkaline-antialka-
line phosphatase (APAAP) system as described previously
(Cordell et al, 1984). Briefly, undecalcified 4-gm sections were
dewaxed in xylene and rehydrated in descending concentrations of
ethanol. For antigen retrieval of the DCC epitope, samples were
boiled in a microwave oven (750 W) for 10 min in citrate buffer
(0.1 M; pH 6.0). After extensive washing in Tris-buffered saline
(145 mm sodium chloride, 20 mm Tris; pH 7.5) the sections were
exposed to the primary antibody (mouse, monoclonal, 8 jig ml-',
PharMingen, no. 15041 A). A secondary rabbit anti-mouse anti-
body (Dako, Hamburg) followed by the APAAP complex (Dako)
was used for detection. Naphtol-AS-biphosphate (Sigma-Aldrich,
Deisenhofen) and Neufuchsin (Merck, Darmstadt) were used for
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Figure 2 DCC mRNA expression in osteosarcoma tumour specimens and
tumour cell lines. (A) Biplex DCCIG6PD RT-PCR. DCCcDNA was amplified
by PCR and analysed on 2% agarose gets. The DCC-specific fragment has a
length of 233 bp. G6PD specific primers were used for control of
amplification efficiency of weakly expressed genes. G6PD primers generated
a product of 149 bp length. M, molecular size marker; lanes 1, 2:
osteosarcoma cell lines TE85, Wo-OS; lanes 3-10: osteosarcoma
specimens OS18, OS17, OS12, OS11, OS21, OS20, OS19, OS5; N, normal
non-malignant osseous tissue. (B) Biplex DCC/1-actin RT-PCR. Agarose gel
electrophoresis of generated DCCproducts (233 bp) and co-amplitied f-actin
fragments (446 bp). Lanes 1-7, 11, 12: osteosarcoma specimens OS7, OS9,
OS3, OS23, OS24, OS8, OS13, OS16, OS14. Lanes 8-10: colon carcinoma
cell lines SW48, SW403, SW948. C, negative control (RT-PCR without RNA
template). Using G6PD-specific primers an intense band was found in OS13,
rendering the vast reduction of DCCexpression a specific event. (C)
Southern analysis of the PCR products presented in (B) using a 1.65-kb
DCCcDNA and a f-actin-specific probe. The signal intensity of DCC-specific
products was used for semiquantitation of DCC mRNA expression
light microscopic visualization of the signal. Normal colon
mucosa served as positive control, whereas for negative controls
the primary antibody was omitted.
Flow-cytometric analysis of DCCexpression
An indirect immunofluorescent technique was performed using a
Becton Dickinson FACS scan as described previously (Pollice et al,
1992). The specific antibody (mouse, monoclonal, PharMingen)
was again directed against the intracytoplasmic domain of the
DCC protein.
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Table 3 DCC expression analysis
Specimen Relative abundance RT-PCR Immunoblot IHC/
of DCCtranscripts AUC (A) flowcytometry
Normal osteoblast
OSi
OS2
OS3
OS4
OS5
OS6
OS7
OS8
OS9
OSlo
OS1i
OS12
OS13
OS14
OS15
OS16
OS17
OS18
OS19
OS20
OS21
OS22
OS23
OS24
OS25
Cell lines
TE85
Saos-2
KHOS-240S
U-2 OS
Wo-OS
RD-ES
A-204
CCRF-CEM
SW48
SW403
SW948
SW1116
HCT116
SW1463
+++
+++
+++
+++
+++
+
+
(-)
(-)
(-)
(-)
(-)
(-)
(-)
(-)
+
++
++
(+)
++
(-)
(+)
(+)
++
8.3 (+0.78 s.d.) Negative
10.0
9.5
8.3
8.9
7.8
5.2
4.6
5.2
2.3
3.8
3.5
0.9
0
0.9
0.3
0.3
0.4
1.1
0.8
7.2
0.7
2.6
7.5
4.7
6.9
0
0
0
2.1
0
5.8
0
0
4.6
0
0.8
2.2
1.6
6.1
Negative
Negative
Negative
Negative
ND
ND
ND
Negative
ND
ND
ND
ND
ND
ND
ND
ND
Negative
ND
ND
ND
ND
ND
ND
Negative
Negative
Negative
Negative
Negative
Negative
ND
Positive
Negative
Negative
ND
ND
ND
ND
ND
ND
Normal osteoblast: normal bone tissue devoid of bone marrow cells was used for RT-PCR and immunoblot analysis; DCC
expression of normally differentiated osteoblasts was confirmed by immunohistochemistry. OS, osteogenic sarcoma. Origins
of cell lines are listed in Table 2 The relative abundance of DCC-specific transcripts was determined by a semiquantitative
RT-PCR-based assay. After Southern transfer, DCC PCR products were hybridized with a 32P-CTP-labelled DCCcDNA. The
intensity of the autoradiographic signals, which reflect the relative amounts of DCCtranscripts, was measured
densitometrically as the area under the curve of absorption AUC (A). AUCs were compared with AUC (A) values based on
DCC PCR data from serially diluted cDNAs of normal osseous tissue specimens (Figure 1). Semiquantitation of AUCs
(A): ++++, DCCexpression > normal osseous tissue; +++, 1:1-1:10 dilution of normal osteoblast cDNA; ++, > 1:10
< 1:20 dilution; +, > 1:20 <1:50; (+), > 1:50<1:100; (-), >1:100 dilution; - DCC expression detectable. IHC,
immunohistochemistry: -, negative; (+), very faint, +, weak, ++, moderate; +++, strong IHC staining intensity for monoclonal
anti-DCC antibody directed against the intracytoplasmatic domain. a Negative staining of transformed osteoblasts, faint DCC
positivity of granulation tissue cells. b FACS scan flowcytometric analysis only; s.d., standard deviation; ND, not determined.
RESULTS
DCC mRNA expression
Northern analysis was largely unsuccessful in demonstrating any
DCC transcript in normal as well as malignant osseous tissue.
Therefore, a sensitive RT-PCR-based approach was chosen to
amplify DCC transcripts from cDNA to evaluate the level ofDCC
gene expression. In normal osseous tissue, DCC transcription was
consistently detected with a low variability between different indi-
viduals. Autoradiographic signal intensities ofPCR products from
serially diluted cDNAs from normal osseous specimens served as
semiquantitative reference values for the degree ofDCC transcrip-
tion (Figure 1).
The analysis of DCC specific RT-PCR products by gel elec-
trophoresis is demonstrated in Figure 2A and B), which presents a
selection of osteosarcomas and tumour cell lines. As expected, the
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Figure 3 (A) DCC protein expression in various tumourceR lines,
DCCtranscibing osteosarcomas and normal osseous tissue.
Lysates [approximately 100 gg total protein or*high molecular
weightfractbionated protein (> 100 kDa with the use of Centikon
filters)) were studied by SDS-PAGE on 8% gels and an ECL
immunoblot analysis. The DCC protein is expected to migrate in a
rather broad region with a molecularweight of approximately 180
000-210 000. Lanes 1, 9, 10: Ewing's sarcoma cell line RD-ES;
lanes 2-5: T-ALL cell line CCRF-CEM, osteosarcoma ceoR lines
U2-OS, SaOS-2, TE85; anes 6, 7: osteosarcoma specimens
OS25, OS1; lane 8: normal osseous tissue. The faint signals in
lanes 6-8, which co-migrate wifth the DCC protein, are considered
non-specific. (B) FACS scan flowcytometric analysis of DCC
protein expression in Ewing's sarcoma cell line RD-ES, T-ALL cell
line CEM, and osteosarcoma cell lines TE85, SAOS, U20S,
KHOS. With the use of a monoclonal antibody directed against
the cytoplasmic domain of the DCC protein the Ewing's sarcoma
derved call line RD-ES exhibited a positive signal indicated by a
non-confluent peak
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Figure 4 Immunohistochemical analysis of DCC in normally differentiated and transformed osteoblasts. (A) Myositis ossificans. The centripetal osteoblastic
differentiation is linked to an increase in DCC protein expression from undifferentiated mesenchymal cells to mature non-transformed osteoblasts. (B) The
photomicrograph of a human high-grade osteosarcoma (OS 18; predominantly chondroblastic), which revealed a vast reduction in DCC mRNA expression
demonstrates a very faint DCC signal in a few tumour cells. (C) A strong cytoplasmatic DCC signal was detected in an osteoblastic high-grade osteosarcoma
(OS 4) with large amounts of DCC transcripts. (D) DCC protein expression in a low-grade osteosarcoma revealing reduced amounts of DCCtranscripts (OS24).
The DCC signal is detected as a red staining predominantly within the cytoplasm of cells (magnification 120x, counterstaining with haematoxylin)
Southern blot analyses of DCC PCR products (Figure 2C) that
were used for semiquantitation proved more sensitive than the in-
gel measurement of PCR fragments (Figure 2B). Table 3 gives an
overview of DCC RT-PCR data from normal osseous tissue,
tumour specimens and cell lines. Eight out of 19 high-grade
osteosarcomas (six primary tumours, two lung metastases;
OS12-19) had a nearly total extinction of DCC expression with a
relative abundance of DCC transcripts of less than 1 % of normal
osseous tissue cells as estimated from the cDNA dilution graph
delineated in Figure 1. In another six high-grade osteosarcomas
(four primary tumours, one metastasis each in lung and spine;
OS6-11) the DCC transcription was found to be reduced to less
than 5% of normal. A normal or even increased DCC expression
was found in the remaining five high-grade osteosarcomas
comprising three primary tumours and two lung metastases (OS1-
5). Among the three periosteal intermediate-grade osteosarcomas,
two tumours were found to have decreased or almost undetectable
DCC expression (OS21, 22). Two out ofthree low-grade osteosar-
coma specimens (OS24, 25) revealed reduced levels of DCC to
varying degrees, whereas OS23 was found to express DCC tran-
scripts within the range ofnormal bone tissue.
In three cases, two different tumour specimens from one patient
each were analysed by RT-PCR. The lung metastases ofpatient no.
5 almost completely lost the DCC expression within 1 year of
progressive disease (OS5, 19). In patient no. 19 the primary inter-
mediate-grade osteosarcoma initially exhibited a strong DCC
expression, which was lost when the tumour recurred 4 months
later (OS20, 21; Figure 2A). The low-grade osteosarcoma OS24
represents a second local relapse with a rather low level of DCC
expression which was found to be somewhat higher in its
concomitant lung metastasis specimen (OS25).
Most ofthe cell lines investigated in this study demonstrated very
low or even absent DCC expression, that is TE 85, Wo-OS, Saos-2,
U2-OS, A-204, SW 403, SW 948, SW 1116, HCT 116 and CCRF-
CEM. The colon carcinoma cell lines SW1463 and SW48, as well as
the Ewing's sarcoma cell line RD-ES, showed easily detectableDCC
transcripts but at a lower level than that found in normal osteoblasts.
DCC protein expression
The initial studies of endogenous DCC protein expression were
performed on a variety of cell lines (TE 85, Saos-2, U2-OS,
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KHOS-240S, RD-ES, CCRF-CEM) using a combined immuno-
precipitation and immunoblotting assay as well as flow-cytometric
technique. A series of various monoclonal antibodies were tested
that were directed against extra- or intracytoplasmic domains of
the DCC protein. The most reliable results were obtained with use
of a monoclonal antibody vs the intracytoplasmatic domain
(PharminGen). Only the human Ewing's sarcoma cell line RD-ES
demonstrated an approximately Mr 180 000 protein that was
detected both by the immunoblot assay and the flow cytometric
technique (Figure 3A and B). Using the combined immunoprecip-
itation and immunoblot assay, DCC protein expression was not
detectable in a variety of normal osseous tissues or osteosarcomas
revealing high levels of DCC transcription (Figure 3A).
Immunohistochemical analysis, however, proved to be more sensi-
tive than the immunoblot approach. The DCC protein could be
clearly demonstrated in normal osteoblasts/osteocytes (Figure
4A). Moreover, in a subset of 14 available osteosarcomas (see
Table 3) DCC protein expression correlated well with the level of
DCC transcription based on an RT-PCR approach (Figure 4B-D).
In normal tissues, the most pronounced staining for DCC was
found in mature osteocytes/osteoblasts. A less intensive DCC
immunoreactivity was observed in immature mesenchymal cells
presumably differentiating to osteoblastic cells (Figure 4A).
Additionally, a faint to moderately intense staining was found in
macrophages, fibroblasts and sometimes in endothelial cells as
cellular components ofgranulation tissues (data not shown).
DCC rearrangement analysis
To determine whether the abnormalities ofDCC expression could
be related to any gross structural rearrangements we performed
Southern blot analyses of EcoRI-restricted genomic DNA using
the 1.65 DCC cDNA as described above. Originally, this probe
was the longest clone that was isolated during the construction of a
DCC cDNA library from RNA of a colon carcinoma cell line
(Fearon et al, 1990). Gross alterations within the DCC gene were
detected in only two colon carcinoma cell lines (SW 1116, HCT
116) expressing reduced amounts of DCC transcripts, but not in
osteosarcomas and the remaining colon carcinoma cell lines,
which revealed a constitutional hybridization pattern of EcoRI-
restricted genomic DNA (data not shown).
DISCUSSION
In summary, the present study demonstrates a reduction or even a
loss ofDCC gene expression in the majority of human high-grade
osteosarcomas and osteosarcoma cell line derivates. This conclu-
sion could be drawn from DCC RNA as well as protein expression
analyses. In view of the putative tumour-suppressor characteristics
ofthe DCCgene it is tempting to assume that its reduction orloss of
expression in many high-grade osteosarcomas may be important in
the pathogenesis of this tumour entity. As mentioned before a loss
of heterozygosity within the DCC locus has been frequently
observed in other malignancies, and expression studies revealed a
remarkable relationship between DCCexpression, cellulardifferen-
tiation and tumorigenesis. A further line of evidence that the DCC
gene may be a tumour suppressor resulted from functional DCC
transfection studies. The introduction of a full-length DCC cDNA
into nitrosomethylurea-transformed human epithelial cells resulted
in a suppression oftumorigenicity (Klingelhutz et al, 1994).
In colon carcinoma, a loss ofDCCexpression can be considered
a late event in tumourprogression (Kikuchi-Yanoshita et al, 1992).
Moreover, it has been suggested that DCC may act as a metastatic
suppressor in colon carcinoma (Ookawa et al, 1993). We found a
frequent loss or decrease ofDCCexpression not only in metastatic
but also in primary disease, possibly indicating an early metastatic
potential of high-grade osteosarcoma. In fact, 10-20% of patients
have detectable metastases at primary diagnosis, and it has been
assumed that up to 80% of osteosarcomas may have spread occult
micrometastases at diagnosis (Link and Eilber, 1993). In some
cases, however, full transcription of DCC has been found in
metastatic osteosarcoma cells, indicating that its loss offunction is
not a necessary premise for a distant spread postulating alternative
pathways of the metastatic process. The analysis ofDCC expres-
sion in follow-up specimens oftwo cases ofosteosarcoma(OS5, 19
and OS20, 21) suggests, at least in these tumours, an inverse rela-
tionship between the magnitude ofDCCtranscription and progres-
sive disease. It is noteworthy that DCC expression of transformed
osteoblasts does not depend on the production of any specific type
of extracellular matrix, i.e. DCC status correlates rather with the
grading of agiven tumour than with its histological subtype.
In osseous tissue the immunoblot approach to DCC expression
was largely unsuccessful, confirming earlier studies on DCC
protein expression in various other tissues (Hedrick et al, 1994;
Reale et al, 1994). Only the Ewing's sarcoma cell line RD-ES
produced a clear signal at about 180 000 kDa in the immunoblot
analysis. The transmembrane localization ofthe DCC protein may
have rendered immunohistochemistry more suitable for demon-
strating its expression than techniques relying on whole-tissue
homogenates. There is an obvious discrepancy between RD-ES
culture cells and cells from native osseous tissues with regard to
DCC expression in the RT-PCR assay compared with the
immunoblot technique. Using the RT-PCR assay both cell types
demonstratedeasily detectable abundances ofDCCtranscripts. By
contrast, immunoblotting combined with immunoprecipitation
revealed DCC expression only in the RD-ES cells. The lack of
detectable DCC protein in osseous tissue cells might result from
degradation of the protein product during sample preparation and
processing that appears to be more relevant to protease-containing
tissue homogenates than to culture cells.
Of the human tumour cell lines studied, only one colon carci-
noma and the Ewing's sarcoma cell line RD-ES revealed easily
detectable amounts of DCC transcripts, whereas most others were
found to have a substantial decrease in DCCexpression including
the osteosarcoma-derived cell lines. Results from three colon
carcinoma cell lines differ from data obtained in earlier studies
with regard to the extent ofDCC expression (Fearon et al, 1990).
These differences may be attributable to an inconsistent muta-
tional inactivation of the DCC gene or aberrant alternative DCC
mRNA splicing processes, which were described previously
(Reale et al, 1994). A mere tissue culture artefact from the in vitro
growth of cells seems to be unlikely, as we identified several cell
lines with a consistent DCC transcription. Intriguingly, we found
comparably moderate to high abundances of DCC transcripts in
each ofeight investigated Ewing's sarcomas (data not shown) and
the derivative cell line RD-ES, suggesting thatDCC is notlikely to
undergo gene silencing under in vitro conditions.
In most human malignancies, suppressor genes appear to be
inactivated at the DNA level. Numerous molecular mechanisms of
gene inactivation have been described, including point mutations,
chromosomal deletions, rearrangements and insertions. Using a
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1.65-kb DCC cDNA probe we were not able to demonstrate any
rearrangement or deletion in EcoRI-restricted genomic DNA from
osteosarcoma. This probe, however, does not fully constitute the
open reading frame of4341 bp of the DCC gene, and thus neither
rearrangements outside this region nor subtle alterations within
would be detected. More comprehensive studies using a set of
polymorphic 18q probes and mapping strategies in addition to an
exhaustive mutational analysis of the 1.4 Mb DCC gene may be
necessary to search for specific DNA alterations leading to a
decreased DCC transcription in human osteosarcoma. In view of
the enormous size of the DCC gene, mutational analysis is prob-
ably the most laborious way to look for alterations that may specif-
ically inactivate DCC as a tumour-suppressor gene at DNA level.
The hitherto evaluated portions ofthe DCC sequence compose less
than 1% of the gene (Cho et al, 1994; E Fearon, 1996, personal
communication). Furthermore, studies on DCC RNA processing
should complement our approach to the DCC gene in osteosar-
coma, as aberrant alternative splicing of DCC mRNA appears to
play a role in other malignancies (Reale et al, 1994; Ekstrand et al,
1995). Finally, the functional restoration ofthe DCC gene in DCC-
deficient osteosarcoma cells will be of great interest in order to
provide further evidence that DCC serves as a tumour-suppressor
gene in human osteosarcoma and that the loss or decrease of its
expression is more than an epigenetic phenomenon.
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